Related Experiment Video

Updated: Jun 13, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

Kristina A Bryant1, Stan L Block, Sherryl A Baker

  • 1Department of Pediatrics, University of Louisville, Louisville, KY 40292, USA. k0brya01@louisville.edu

Pediatrics
|May 4, 2010
PubMed

Insights

The 13-valent pneumococcal conjugate vaccine (PCV13) demonstrated strong immunogenicity and safety in infants, comparable to the 7-valent pneumococcal conjugate vaccine (PCV7). PCV13 effectively targets additional Streptococcus pneumoniae serotypes, enhancing protection against invasive pneumococcal disease.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Immunology

Background:

  • Invasive pneumococcal disease (IPD) rates have decreased with the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7).
  • However, nonvaccine Streptococcus pneumoniae serotypes continue to cause significant illness and death.
  • The 13-valent pneumococcal conjugate vaccine (PCV13) was developed to broaden protection against additional serotypes.

Purpose of the Study:

  • To compare the safety and immunogenicity of PCV13 against PCV7 in infants.
  • To evaluate antibody responses to both shared and unique serotypes covered by PCV13.

Main Methods:

  • Infants were randomized to receive either PCV13 or PCV7 at 2, 4, and 6 months of age.
  • Antibody concentrations (immunoglobulin G) and functional antibody levels (opsonophagocytic assay - OPA) were measured post-vaccination.
  • Safety was assessed by monitoring local reactions and systemic events.

Main Results:

  • PCV13 elicited robust immunogenic responses across all 13 serotypes, with high percentages of infants achieving protective antibody concentrations.
  • Antibody levels for shared serotypes were comparable between PCV13 and PCV7 groups.
  • OPA titers for PCV13-exclusive serotypes were significantly higher in the PCV13 group, and local/systemic reactions were similar between vaccines.

Conclusions:

  • PCV13 is well-tolerated and immunogenic in infants.
  • The vaccine induces significant antibody and OPA responses to all 13 targeted Streptococcus pneumoniae serotypes.
  • PCV13 offers enhanced protection against a broader range of pneumococcal serotypes compared to PCV7.
Abstract

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...